Rapafusyn Pharmaceuticals is an emerging pharmaceutical development company located in Baltimore Maryland. Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from Johns Hopkins University School of Medicine and seeks to develop novel pharmaceuticals to treat patients having diseases and fulfill unmet medical needs.
Location: United States
Total raised: $72M
Founded date: 2015
Investors 2
| Date | Name | Website |
| 07.06.2021 | 3E Biovent... | 3ebiovc.co... |
| - | Johns Hopk... | ventures.j... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.09.2025 | Series A | $44M | Proxima Ve... |
| 28.06.2024 | Series A | $28M | - |
Mentions in press and media 8
| Date | Title | Description |
| 08.09.2025 | Rapafusyn Pharmaceuticals Closes $44M Series A Financing | Rapafusyn Pharmaceuticals, a Baltimore, MD-based company which specializes in the discovery and development of non-degrading molecular glue therapeutics, raised $44M in Series A funding. The round was led by BioTrack Capital and Yonjin Capi... |
| 28.06.2024 | Rapafusyn Pharmaceuticals: $28 Million Series A Funding Raised To Develop Therapeutic Drugs Based On Non-Degrading Molecular Glues | Rapafusyn Pharmaceuticals, a leader in the discovery and development of therapeutic drugs based on non-degrading molecular glues, announced the initial closings of an extension of its Series A financing, bringing the total round to $28 Mill... |
| 25.06.2024 | Rapafusyn Pharmaceuticals: A Leader in Non-Degrading Molecular Glue Drug Discovery | Rapafusyn Pharmaceuticals, a Baltimore-based company, recently secured $28 million in Series A funding to advance its innovative non-degrading molecular glue drug discovery platform. Led by 3E Bioventures Capital and Proxima Ventures Ltd., ... |
| 24.06.2024 | Rapafusyn Pharmaceuticals Raises $28M in Series A Funding | Rapafusyn Pharmaceuticals, a Baltimore, MD-based company which specializes in the discovery and development of therapeutic drugs based on non-degrading molecular glues, raised $28M in Series A funding. The round was led by 3E Bioventures Ca... |
| 20.06.2024 | Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform | Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets Financing led by 3E Bioventures Capital and Proxim... |
| 02.02.2024 | Rapafusyn's Rick Ewing Acknowledged with Dual Honors for Exceptional Achievements | BALTIMORE, MARYLAND, USA, February 2, 2024 /EINPresswire.com/ -- Rapafusyn proudly announces the distinguished recognition of Dr. Rick Ewing, Vice President of Medicinal Chemistry, for his outstanding contributions to the realms of chemistr... |
| - | Rapafusyn Pharmaceuticals | “Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.” |
| - | Rapafusyn Pharmaceuticals | “RAPAFUSYN” |